BD completes acquisition of Bard

BD has announced the completion of its acquisition of fellow medical technology firm Bard, a deal that will establish BD as a new healthcare industry leader.

The combined company is positioned to deliver improvements in both the treatment of disease and the process of providing care, expanding BD's existing medication management and infection prevention leadership with an expanded offering of solutions.

It is expected that the new-look business will generate around $16 billion (11.8 billion pounds) in annualised revenue, with Bard's portfolio and innovation pipeline expanding BD's opportunities in fast-growing clinical areas, especially in non-US markets.

Bard will now operate as a wholly-owned subsidiary of BD, with around 16,000 members of Bard's staff set to transition across as part of the merger.

Vincent Forlenza, chairman and chief executive officer of BD, said: "We look forward to continuing to lead the industry through innovation and partnerships that bring more valuable solutions to our customers and their patients."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.